151 related articles for article (PubMed ID: 32156507)
1. Re: Karl H. Tully, David-Dan Nguyen, Peter Herzog, et al. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2019.08.003.
Fragkoulis C; Glykas I; Papadopoulos G; Ntoumas K
Eur Urol Oncol; 2020 Dec; 3(6):809-810. PubMed ID: 32156507
[No Abstract] [Full Text] [Related]
2. Re: Jian Pan, Yu Wei, Tingwei Zhang, et al. Stereotactic Radiotherapy for Lesions Detected via
Guler OC; Onal C
Eur Urol Oncol; 2022 Aug; 5(4):475-476. PubMed ID: 35577749
[No Abstract] [Full Text] [Related]
3. Reply to Ozan Cem Guler and Cem Onal's Letter to the Editor re: Jian Pan, Yu Wei, Tingwei Zhang, et al. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wang B; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):479. PubMed ID: 35710620
[No Abstract] [Full Text] [Related]
4. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
Goonewardene SS; Persad R; Young A; Makar A
Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
[No Abstract] [Full Text] [Related]
5. Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.01.020.
Jung J; Kim JH
Eur Urol; 2023 Sep; 84(3):e73-e74. PubMed ID: 37202316
[No Abstract] [Full Text] [Related]
6. Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25.
Montorsi F; Barletta F; Gandaglia G
Eur Urol Oncol; 2023 Aug; 6(4):451. PubMed ID: 36707322
[No Abstract] [Full Text] [Related]
7. Re: Rhonda L. Bitting, Patrick Healy, Daniel J. George, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol 2021;4:948-54.
Guler OC; Isci O; Onal C
Eur Urol Oncol; 2022 Aug; 5(4):477-478. PubMed ID: 35307322
[No Abstract] [Full Text] [Related]
8. Re: Karim A. Touijer, Daniel D. Sjoberg, Nicole Benfante, et al. Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.03.006.
Yang B; Yang G; Yao X
Eur Urol Oncol; 2021 Oct; 4(5):852-853. PubMed ID: 34535419
[No Abstract] [Full Text] [Related]
9. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
Kirollos MM
Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
[No Abstract] [Full Text] [Related]
10. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006.
Onal C; Elmali A; Cem Guler O
Eur Urol Oncol; 2024 Jun; 7(3):644-645. PubMed ID: 38365504
[No Abstract] [Full Text] [Related]
11. Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
Gandaglia G; Sun M; Briganti A; Karakiewicz PI
Eur Urol; 2014 Aug; 66(2):e36-7. PubMed ID: 24746970
[No Abstract] [Full Text] [Related]
12. Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
Stephan C; Cammann H; Jung K
Eur Urol; 2015 Nov; 68(5):e106-7. PubMed ID: 26215600
[No Abstract] [Full Text] [Related]
13. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
van Soest RJ; de Wit R; van Weerden WM
Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
[No Abstract] [Full Text] [Related]
14. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Lombardo R; Riolo S; De Nunzio C
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37872030
[No Abstract] [Full Text] [Related]
15. Re: Hein V. Stroomberg, Signe Benzon Larsen, Torben Kjær Nielsen, J. Thomas Helgstrand, Klaus Brasso, Andreas Røder. Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.005.
Gallo G; Lombardo R; De Nunzio C
Eur Urol Oncol; 2024 Jun; 7(3):646-647. PubMed ID: 38290922
[No Abstract] [Full Text] [Related]
16. Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
Parker C; Sydes MR; Kynaston H;
Eur Urol; 2013 Nov; 64(5):e102. PubMed ID: 23953599
[No Abstract] [Full Text] [Related]
17. Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039.
Alongi F; Aiello D; Mazzola R; Cavalleri S
Eur Urol; 2017 Aug; 72(2):e39-e40. PubMed ID: 28318727
[No Abstract] [Full Text] [Related]
18. Re: Felix Seelemeyer, David Pfister, Robert Pappesch, et al. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021.
Urabe F; Yoshioka T; Kimura T
Eur Urol Oncol; 2024 Apr; 7(2):307. PubMed ID: 38238224
[No Abstract] [Full Text] [Related]
19. Re: Jean-Pierre Droz, Gilles Albrand, Silke Gillessen, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.12.025: Health Assessment of the Elderly is a "Relatively Young" Issue.
Dal Moro F; Motterle G; Barbieri L; Zattoni F
Eur Urol; 2017 May; 71(5):e150-e151. PubMed ID: 28216172
[No Abstract] [Full Text] [Related]
20. Re: Christian Bolenz, Stephen J. Freedland, Brent K. Hollenbeck, et al. costs of radical prostatectomy for prostate cancer: a systematic review. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.059.
Rassweiler J
Eur Urol; 2013 Apr; 63(4):e53-6. PubMed ID: 23312570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
